A Randomized, Double‐Blind, Parallel Group, Placebo‐ Controlled Multi‐Centre Phase Iii Study To Assess The Efficacy And Safety Of Olaparib Versus Placebo as Adjuvant Treatment In Patients With Germline BRCA 1/2 Mutations And High Risk Her2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment And Neoadjuvant Or Adjuvant Chemotherapy
Read more about this trial →← Back to available clinical trials